Overall, there is a tendency for CD19‐CAR T cells to be most effective in patients suffering from ALL, slightly less so for NHL, and the least for chronic lymphocytic leukemia (CLL), suggesting an influence of the disease type on efficacy. Here, CD19 is linked to acute lymphoblastic leukemia.